Published in:
01-12-2011 | Original Paper
MDR-1 polymorphisms (G2677T and C3435T) in B-chronic lymphocytic leukemia: an impact on susceptibility and prognosis
Authors:
G. Penna, A. Allegra, A. Alonci, M. Aguennouz, A. Garufi, A. Cannavò, D. Gerace, A. Alibrandi, C. Musolino
Published in:
Medical Oncology
|
Issue 4/2011
Login to get access
Abstract
Patients with B-chronic lymphocytic leukemia present diverse clinical features, genetic abnormalities, variable response to treatment, and heterogeneous prognosis. Novel biological markers such as IgVH mutation, CD38, and ZAP-70 expression have shown to offer important prognostic information. An altered expression of the multidrug resistance 1 may represent an additional prognostic marker. Aim of our study was to evaluate two MDR-1 gene polymorphisms: G2677T polymorphism in exon 21 and C3435T polymorphism in exon 26, to evidence if polymorphisms influence the risk of development of B-CLL and whether genomic polymorphisms provide prognostic information on the clinical progression of the disease. A total of 125 patients with B-CLL and 125 healthy subjects were enrolled in this study. The mutant homozygous 2677 TT genotype was found to be associated with the occurrence of B-CLL and higher T allele frequency in patients with B-CLL when compared with controls was observed (P = 0.009). When comparing the prognostic patients’ characteristics, patients with 2677 GT genotype were statistically linked to the unmutated IgVH genes (r = 0.209, P = 0.01). Moreover, the same genotype was correlated with lymphocyte number (r = 0.269, P = 0.02). Finally for the 2677GT polymorphism, the heterozygous status was associated with higher hemoglobin levels (r = 0.247, P = 0.005). As far the C3435T MDR1 polymorphism, we were not able to identify any significant correlation with IgVH gene status or other variables. In conclusion, MDR1 gene polymorphism could be a factor predisposing to LLC. Moreover, our findings support the possibility of considering these genomic polymorphisms as prognostic markers in patients with B-CLL.